BOOM! Huge news: Stemson on track to bless us with the holy grail soon!

Joxy

Experienced Member
Reaction score
517
Takashi Kondo again confirmed that they are starting clinical trials somewhere in the second half of 2024. Stemson has very slow process of entering clinical trials. At least 10-12 years from now, so they will loose a big portion of the hair loss market.
 

Joxy

Experienced Member
Reaction score
517

Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth​

Demonstrates new engineered functional hair follicles in humanized mice

SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials. Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles and has successfully created human hair follicles in humanized mice using engineered follicular units. The engineered follicular units are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications, including Androgenetic Alopecia, Scarring Alopecia, and Chemo-Induced Alopecia.


 

Joxy

Experienced Member
Reaction score
517

Stemson bolsters executive team with Chief Development Officer and VP Data Sciences & Bioinformatics​


February 6, 2024
Stemson Therapeutics announced today the promotion of Meghan Samberg, PhD, to Chief Development Officer, and Nick Wisniewski, PhD, to Vice President Data Sciences and Bioinformatics. The promotions move Stemson firmly into the final stages of product development with an emphasis on leveraging bioengineering, big data, and machine learning approaches to create a highly controlled and reproducible therapeutic outcome for hair growth.

 

Joxy

Experienced Member
Reaction score
517
“The work we are doing at Stemson Therapeutics will revolutionize how many forms of hair loss are treated in the future. The Stemson team is motivated every day to help people who are devastated by their hair loss. I am truly excited about the announcement we made today demonstrating a significant leap forward in our therapeutic development efforts. We're getting much closer!“


This is still at least 10-12 years away from practical use, and at least 15 years away from ordinary Joe in USA.
 

MrClean1

Established Member
My Regimen
Reaction score
69
“The work we are doing at Stemson Therapeutics will revolutionize how many forms of hair loss are treated in the future. The Stemson team is motivated every day to help people who are devastated by their hair loss. I am truly excited about the announcement we made today demonstrating a significant leap forward in our therapeutic development efforts. We're getting much closer!“


This is still at least 10-12 years away from practical use, and at least 15 years away from ordinary Joe in USA.
Hopefully my son will benefit from it and won't have to go through the shitty choices we have.
 

dsd

New Member
Reaction score
5
Stemson has many employees on their website. No selling product. Don't understand reasons of hairloss. They want to grow genetically hair. Who wants to have those implanted? Anyway in the normal hair transplantation the hairs of the donor area shrink on the bald areas. Same would happen to the Stemson hairs.
For me this is a fairy tale.
 

Joxy

Experienced Member
Reaction score
517
Stemson has many employees on their website. No selling product. Don't understand reasons of hairloss. They want to grow genetically hair. Who wants to have those implanted? Anyway in the normal hair transplantation the hairs of the donor area shrink on the bald areas. Same would happen to the Stemson hairs.
For me this is a fairy tale.
Those hairs will be identical to your native hair, because they are created from your human stem cells with normal hair cycle and size.
 

dsd

New Member
Reaction score
5
Those hairs will be identical to your native hair, because they are created from your human stem cells with normal hair cycle and size.
The theory is cool. But what if something starts growing next to your new follicles? There is not much flesh to cut it away. Then your not even bald but skull.
 

Joxy

Experienced Member
Reaction score
517
The theory is cool. But what if something starts growing next to your new follicles? There is not much flesh to cut it away. Then your not even bald but skull.
Only human trials will tell us the end results. All the experiments that they are doing now doesn’t tumors traits.
 

Joxy

Experienced Member
Reaction score
517
Which technology you think it will translate best and it will be far less complicated for ordinary doctors to perform it? OrganTech have closed their product and it is ready for human clinical trials. Stemson is at least 10-15 years for practical use.
 

Joxy

Experienced Member
Reaction score
517
New interview with Stemson Therapeutics. Based on the interview they still need to solve some things to get their technology finally to clinical trials.

 

Derek Clapton

Member
Reaction score
24
10-12 years is ludicrous. How on earth are they keeping a company afloat for that long with such slow development? It's such a huge issue that could make so much money, I don't understand why nobody has got a solution yet and we have these clowns taking forever to develop stuff.
 

Joxy

Experienced Member
Reaction score
517
10-12 years is ludicrous. How on earth are they keeping a company afloat for that long with such slow development? It's such a huge issue that could make so much money, I don't understand why nobody has got a solution yet and we have these clowns taking forever to develop stuff.
Actually, hair loss market is not that huge. Plus, hair cloning is extremely expensive and not cost-effective for companies to invest.
 

Joxy

Experienced Member
Reaction score
517
Stemson and Aderans new partnership and transfer technology.

Stemson Therapeutics and Bosley Parent Company, Aderans, Sign Exclusive Hair Regeneration Licensing Deal​


SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics and Aderans Company, the parent company of Bosley® and HAIRCLUB®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology. Stemson, a leader in developing a proprietary cell therapy technology for reversing hair loss based on induced pluripotent stem cells (iPSC), gains a complementary technology through this agreement. Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair regeneration program, integrate the technology into its existing hair loss cell therapy development pipeline, and provide multiple products for patients experiencing hair loss.

Aderans’ proprietary hair regeneration platform is a cell therapy system that utilizes patient-derived hair and skin cells to durably rejuvenate shrinking hair follicles in patients with Androgenetic Alopecia by repopulating functional hair follicle cells into early-to-mid stage hair loss areas. Aderans Co., a Tokyo-based global leader in hair products and services, conducted Phase 2 clinical testing in the United States on 445 human patients to treat early-to-mid stage Androgenetic Alopecia in men and women. Initial clinical data suggest a single dose of functional hair follicle cells into the target scalp area can safely produce long lasting and durable hair growth results. Stemson intends to leverage this technology as it continues development of iPSC-derived autologous cell therapy to regenerate healthy hair follicles. Stemson has successfully created human hair follicles in humanized mice using engineered follicular units which are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications.


They became aware that iPSCs - based hair cloning technology is very complicated and far away from clinical trials and commercialization, so they need something easier and safer to start making money and survive the market.
 

Joxy

Experienced Member
Reaction score
517
New interview with Geoff Hamilton. So, interesting question in 57:30. They actually don’t believe that they can get 120cm per square coverage or I didn’t understand him correctly? No full of head?

 
Last edited:
Top